Trial Profile
A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumour (GIST) Patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Biomarker; Therapeutic Use
- 24 Aug 2010 Merck and Co added as trial sponsor and Schering/Merck as lead trial centre as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Sep 2008 Status changed from recruiting to active, no longer recruiting.